Pulmonary Hypertension Associated with Left Heart Disease

 

 Buy Article Permissions and Reprints

Abstract

Left heart disease (LHD) is probably the most frequent cause of pulmonary hypertension (PH). Although rheumatic mitral valve stenosis has been in the past the most common cause of this condition, PH-LHD mainly results from heart failure related to systolic and/or diastolic dysfunction of the left ventricle and is associated with elevated left-sided cardiac filling pressures. Most patients have passive increase in pulmonary arterial pressure because of backward transmission of the elevated left atrial pressure, whereas a small subset develop severe PH with elevated transpulmonary gradient and pulmonary vascular resistance. When present, PH is usually associated with a poor prognosis and increased mortality. Optimizing heart failure regimens and corrective valve surgery are the cornerstones of the treatment of PH in LHD. Although PH-LHD may evolve to right ventricular failure and is associated with some changes in the pulmonary vascular bed similar to pulmonary arterial hypertension (PAH), there is no evidence-based data to support the use of PAH-specific therapies in the setting of PH-LHD. However, recent studies suggest the usefulness of sildenafil, a phosphodiesterase-5 inhibitor. This review addresses the epidemiology, pathophysiology, risk factors, and treatment controversies of PH due to LHDs.

• References

• 1 McLaughlin VV, Archer SL, Badesch DB , et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53 (17) 1573-1619
  CrossrefPubMedGoogle Scholar
• 2 Galiè N, Hoeper MM, Humbert M , et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34 (6) 1219-1263
  CrossrefPubMedGoogle Scholar
• 3 Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006; 119 (12) (Suppl. 01) S3-S10
  PubMedGoogle Scholar
• 4 Lucas C, Johnson W, Hamilton MA , et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000; 140 (6) 840-847
  CrossrefPubMedGoogle Scholar
• 5 Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 2007; 28 (1) 233-241 , x
  CrossrefPubMedGoogle Scholar
• 6 Rich S, Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation 2008; 118 (21) 2190-2199
  CrossrefPubMedGoogle Scholar
• 7 Haddad F, Kudelko K, Mercier O, Vrtovec B, Zamanian RT, de Jesus Perez V. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis 2011; 54 (2) 154-167
  CrossrefPubMedGoogle Scholar
• 8 Shapiro BP, Nishimura RA, McGoon MD , et al. Diagnostic dilemmas: diastolic heart failure causing pulmonary hypertension and pulmonary hypertension causing diastolic dysfunction.Adv. Pulmon Hypertens 2006; 5: 13-20
  PubMedGoogle Scholar
• 9 Hoeper MM, Barberà JA, Channick RN , et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1) (Suppl): S85-S96
  CrossrefPubMedGoogle Scholar
• 10 Kay JM, Edwards FR. Ultrastructure of the alveolar-capillary wall in mitral stenosis. J Pathol 1973; 111 (4) 239-245
  CrossrefPubMedGoogle Scholar
• 11 Lee Y-S. Electron microscopic studies on the alveolar-capillary barrier in the patients of chronic pulmonary edema. Jpn Circ J 1979; 43 (10) 945-954
  CrossrefPubMedGoogle Scholar
• 12 Townsley MI, Fu Z, Mathieu-Costello O, West JB. Pulmonary microvascular permeability. Responses to high vascular pressure after induction of pacing-induced heart failure in dogs. Circ Res 1995; 77 (2) 317-325
  CrossrefPubMedGoogle Scholar
• 13 Drake RE, Doursout MF. Pulmonary edema and elevated left atrial pressure: four hours and beyond. News Physiol Sci 2002; 17: 223-226
  PubMedGoogle Scholar
• 14 Wagenvoort C, Wagenvoort N. Pathology of Pulmonary Hypertension. 2nd ed. New York, NY: John Wiley & Sons; 1977
  Google Scholar
• 15 Delgado JF, Conde E, Sánchez V , et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005; 7 (6) 1011-1016
  CrossrefPubMedGoogle Scholar
• 16 Du L, Sullivan CC, Chu D , et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003; 348 (6) 500-509
  CrossrefPubMedGoogle Scholar
• 17 Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000; 102 (14) 1718-1723
  CrossrefPubMedGoogle Scholar
• 18 Porter TR, Taylor DO, Cycan A , et al. Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol 1993; 22 (5) 1418-1424
  CrossrefPubMedGoogle Scholar
• 19 Cooper CJ, Jevnikar FW, Walsh T, Dickinson J, Mouhaffel A, Selwyn AP. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol 1998; 82 (5) 609-614
  CrossrefPubMedGoogle Scholar
• 20 Yanagisawa M, Kurihara H, Kimura S , et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332 (6163) 411-415
  CrossrefPubMedGoogle Scholar
• 21 Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61 (2) 227-237
  CrossrefPubMedGoogle Scholar
• 22 Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85 (2) 504-509
  CrossrefPubMedGoogle Scholar
• 23 Rodeheffer RJ, Lerman A, Heublein DM, Burnett Jr JC. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992; 67 (8) 719-724
  CrossrefPubMedGoogle Scholar
• 24 Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994; 23 (6) 1427-1433
  CrossrefPubMedGoogle Scholar
• 25 Fukuroda T, Kobayashi M, Ozaki S , et al. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol 1994; 76 (5) 1976-1982
  PubMedGoogle Scholar
• 26 Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996; 81 (4) 1510-1515
  PubMedGoogle Scholar
• 27 Drazner MH, Hamilton MA, Fonarow G, Creaser J, Flavell C, Stevenson LW. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 1999; 18 (11) 1126-1132
  CrossrefPubMedGoogle Scholar
• 28 Drazner MH, Prasad A, Ayers C , et al. The relationship of right- and left-sided filling pressures in patients with heart failure and a preserved ejection fraction. Circ Heart Fail 2010; 3 (2) 202-206
  CrossrefPubMedGoogle Scholar
• 29 Zener JC, Hancock EW, Shumway NE, Harrison DC. Regression of extreme pulmonary hypertension after mitral valve surgery. Am J Cardiol 1972; 30 (8) 820-826
  CrossrefPubMedGoogle Scholar
• 30 Levine MJ, Weinstein JS, Diver DJ , et al. Progressive improvement in pulmonary vascular resistance after percutaneous mitral valvuloplasty. Circulation 1989; 79 (5) 1061-1067
  CrossrefPubMedGoogle Scholar
• 31 Fawzy ME, Hassan W, Stefadouros M, Moursi M, El Shaer F, Chaudhary MA. Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy. J Heart Valve Dis 2004; 13 (6) 942-947 , discussion 947–948
  PubMedGoogle Scholar
• 32 Costard-Jäckle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992; 19 (1) 48-54
  CrossrefPubMedGoogle Scholar
• 33 Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 2010; 106 (2) 284-286
  CrossrefPubMedGoogle Scholar
• 34 Thenappan T, Shah SJ, Gomberg-Maitland M , et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2011; 4 (3) 257-265
  CrossrefPubMedGoogle Scholar
• 35 Buchbinder N, Ganz W. Hemodynamic monitoring: invasive techniques. Anesthesiology 1976; 45 (2) 146-155
  CrossrefPubMedGoogle Scholar
• 36 Chemla D, Castelain V, Hervé P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002; 20 (5) 1314-1331
  CrossrefPubMedGoogle Scholar
• 37 Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history?. J Am Coll Cardiol 2001; 38 (5) 1277-1282
  CrossrefPubMedGoogle Scholar
• 38 Nootens M, Wolfkiel CJ, Chomka EV, Rich S. Understanding right and left ventricular systolic function and interactions at rest and with exercise in primary pulmonary hypertension. Am J Cardiol 1995; 75 (5) 374-377
  CrossrefPubMedGoogle Scholar
• 39 Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 1999; 34 (6) 1802-1806
  CrossrefPubMedGoogle Scholar
• 40 Franciosa JA, Baker BJ, Seth L. Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. Am Heart J 1985; 110 (4) 807-813
  CrossrefPubMedGoogle Scholar
• 41 Givertz MM, Hare JM, Loh E, Gauthier DF, Colucci WS. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol 1996; 28 (7) 1775-1780
  CrossrefPubMedGoogle Scholar
• 42 Ha JW, Choi D, Park S , et al. Determinants of exercise-induced pulmonary hypertension in patients with normal left ventricular ejection fraction. Heart 2009; 95 (6) 490-494
  CrossrefPubMedGoogle Scholar
• 43 Shim CY, Kim SA, Choi D , et al. Clinical outcomes of exercise-induced pulmonary hypertension in subjects with preserved left ventricular ejection fraction: implication of an increase in left ventricular filling pressure during exercise. Heart 2011; 97 (17) 1417-1424
  CrossrefPubMedGoogle Scholar
• 44 Maeder MT, Thompson BR, Brunner-La Rocca HP, Kaye DM. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol 2010; 56 (11) 855-863
  CrossrefPubMedGoogle Scholar
• 45 Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3 (5) 588-595
  CrossrefPubMedGoogle Scholar
• 46 Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995; 25 (5) 1143-1153
  CrossrefPubMedGoogle Scholar
• 47 Reindl I, Wernecke KD, Opitz C , et al. Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction. Am Heart J 1998; 136 (5) 778-785
  CrossrefPubMedGoogle Scholar
• 48 Methvin AB, Owens AT, Emmi AG , et al. Ventilatory inefficiency reflects right ventricular dysfunction in systolic heart failure. Chest 2011; 139 (3) 617-625
  CrossrefPubMedGoogle Scholar
• 49 Lewis GD, Shah RV, Pappagianopolas PP, Systrom DM, Semigran MJ. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. Circ Heart Fail 2008; 1 (4) 227-233
  CrossrefPubMedGoogle Scholar
• 50 Lewis GD, Murphy RM, Shah RV , et al. Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. Circ Heart Fail 2011; 4 (3) 276-285
  CrossrefPubMedGoogle Scholar
• 51 Croft JB, Giles WH, Pollard RA, Keenan NL, Casper ML, Anda RF. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999; 159 (5) 505-510
  CrossrefPubMedGoogle Scholar
• 52 Davis RC, Hobbs FD, Kenkre JE , et al. Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ 2002; 325 (7373) 1156
  CrossrefPubMedGoogle Scholar
• 53 Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med 2004; 351 (11) 1097-1105
  CrossrefPubMedGoogle Scholar
• 54 Zafrir B, Paz H, Wolff R , et al. Mortality rates and modes of death in heart failure patients with reduced versus preserved systolic function. Eur J Intern Med 2011; 22 (1) 53-56
  CrossrefPubMedGoogle Scholar
• 55 Ghio S, Gavazzi A, Campana C , et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37 (1) 183-188
  CrossrefPubMedGoogle Scholar
• 56 Klapholz M, Maurer M, Lowe AM , et al; New York Heart Failure Consortium. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 2004; 43 (8) 1432-1438
  CrossrefPubMedGoogle Scholar
• 57 Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53 (13) 1119-1126
  CrossrefPubMedGoogle Scholar
• 58 Neuman Y, Kotliroff A, Bental T, Siegel RJ, David D, Lishner M. Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. Int J Cardiol 2008; 127 (2) 174-178
  CrossrefPubMedGoogle Scholar
• 59 Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355 (3) 251-259
  CrossrefPubMedGoogle Scholar
• 60 Amir O, Paz H, Rogowski O , et al. Serum oxidative stress level correlates with clinical parameters in chronic systolic heart failure patients. Clin Cardiol 2009; 32 (4) 199-203
  CrossrefPubMedGoogle Scholar
• 61 Rogowski O, Shnizer S, Wolff R, Lewis BS, Amir O. Increased serum levels of oxidative stress are associated with hospital readmissions due to acute heart failure. Cardiology 2011; 118 (1) 33-37
  CrossrefPubMedGoogle Scholar
• 62 Amir O, Rogowski O, David M, Lahat N, Wolff R, Lewis BS. Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha. Isr Med Assoc J 2010; 12 (3) 158-162
  PubMedGoogle Scholar
• 63 Paulus WJ, Tschöpe C, Sanderson JE , et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28 (20) 2539-2550
  CrossrefPubMedGoogle Scholar
• 64 Amir RE, Amir O, Paz H , et al. Genotype-phenotype associations between chymase and angiotensin-converting enzyme gene polymorphisms in chronic systolic heart failure patients. Genet Med 2008; 10 (8) 593-598
  CrossrefPubMedGoogle Scholar
• 65 Amir O, Amir RE, Paz H, Mor R, Sagiv M, Lewis BS. Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol 2008; 102 (3) 326-329
  CrossrefPubMedGoogle Scholar
• 66 Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012; 14 (2) 147-154
  CrossrefPubMedGoogle Scholar
• 67 McMurray JJ, Adamopoulos S, Anker SD , et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14 (8) 803-869
  CrossrefPubMedGoogle Scholar
• 68 Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004; 43 (3) 317-327
  CrossrefPubMedGoogle Scholar
• 69 McMurray JJ, Carson PE, Komajda M , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008; 10 (2) 149-156
  CrossrefPubMedGoogle Scholar
• 70 Dwyer EM, Asif M, Ippolito T, Gillespie M. Role of hypertension, diabetes, obesity, and race in the development of symptomatic myocardial dysfunction in a predominantly minority population with normal coronary arteries. Am Heart J 2000; 139 (2 Pt 1) 297-304
  CrossrefPubMedGoogle Scholar
• 71 de las Fuentes L, Brown AL, Mathews SJ , et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J 2007; 28 (5) 553-559
  PubMedGoogle Scholar
• 72 Robbins IM, Newman JH, Johnson RF , et al. Association of the metabolic syndrome with pulmonary venous hypertension. Chest 2009; 136 (1) 31-36
  CrossrefPubMedGoogle Scholar
• 73 Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003; 107 (5) 714-720
  CrossrefPubMedGoogle Scholar
• 74 Tedford RJ, Hassoun PM, Mathai SC , et al. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 2012; 125 (2) 289-297
  CrossrefPubMedGoogle Scholar
• 75 Walston A, Peter RH, Morris JJ, Kong Y, Behar VS. Clinical implications of pulmonary hypertension in mitral stenosis. Am J Cardiol 1973; 32 (5) 650-655
  CrossrefPubMedGoogle Scholar
• 76 Bonow RO, Carabello BA, Chatterjee K , et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006; 48 (3) e1-e148
  CrossrefPubMedGoogle Scholar
• 77 Alexopoulos D, Lazzam C, Borrico S, Fiedler L, Ambrose JA. Isolated chronic mitral regurgitation with preserved systolic left ventricular function and severe pulmonary hypertension. J Am Coll Cardiol 1989; 14 (2) 319-322
  CrossrefPubMedGoogle Scholar
• 78 Silver K, Aurigemma G, Krendel S, Barry N, Ockene I, Alpert J. Pulmonary artery hypertension in severe aortic stenosis: incidence and mechanism. Am Heart J 1993; 125 (1) 146-150
  CrossrefPubMedGoogle Scholar
• 79 Naidoo DP, Mitha AS, Vythilingum S, Chetty S. Pulmonary hypertension in aortic regurgitation: early surgical outcome. Q J Med 1991; 80 (291) 589-595
  PubMedGoogle Scholar
• 80 Angeja BG, Grossman W. Evaluation and management of diastolic heart failure. Circulation 2003; 107 (5) 659-663
  CrossrefPubMedGoogle Scholar
• 81 Rich S, Dantzker DR, Ayres SM , et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107 (2) 216-223
  CrossrefPubMedGoogle Scholar
• 82 Baker BJ, Wilen MM, Boyd CM, Dinh H, Franciosa JA. Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure. Am J Cardiol 1984; 54 (6) 596-599
  CrossrefPubMedGoogle Scholar
• 83 Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3 (5) 588-595
  CrossrefPubMedGoogle Scholar
• 84 Januzzi Jr JL. Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure. Cleve Clin J Med 2006; 73 (2) 149-152 , 155–157
  CrossrefPubMedGoogle Scholar
• 85 Dickstein K, Cohen-Solal A, Filippatos G , et al; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29 (19) 2388-2442
  CrossrefPubMedGoogle Scholar
• 86 Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quiñones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30 (6) 1527-1533
  CrossrefPubMedGoogle Scholar
• 87 Stojnic BB, Brecker SJ, Xiao HB, Helmy SM, Mbaissouroum M, Gibson DG. Left ventricular filling characteristics in pulmonary hypertension: a new mode of ventricular interaction. Br Heart J 1992; 68 (1) 16-20
  CrossrefPubMedGoogle Scholar
• 88 Moustapha A, Kaushik V, Diaz S, Kang SH, Barasch E. Echocardiographic evaluation of left-ventricular diastolic function in patients with chronic pulmonary hypertension. Cardiology 2001; 95 (2) 96-100
  CrossrefPubMedGoogle Scholar
• 89 Little WC, Badke FR, O'Rourke RA. Effect of right ventricular pressure on the end-diastolic left ventricular pressure-volume relationship before and after chronic right ventricular pressure overload in dogs without pericardia. Circ Res 1984; 54 (6) 719-730
  CrossrefPubMedGoogle Scholar
• 90 Sunagawa K, Maughan W, Weisfeldt M , et al. Effect of systolic transseptal pressure on septal elastance and ventricular cross-talk. [abstract] Circulation 1981; 64 (Suppl IV ): 180
  PubMedGoogle Scholar
• 91 Lam CS. Heart failure with preserved ejection fraction: invasive solution to diagnostic confusion?. J Am Coll Cardiol 2010; 55 (16) 1711-1712
  CrossrefPubMedGoogle Scholar
• 92 Walston II A, Kendall ME. Comparison of pulmonary wedge and left atrial pressure in man. Am Heart J 1973; 86 (2) 159-164
  CrossrefPubMedGoogle Scholar
• 93 Fishman AP. A century of pulmonary hemodynamics. Am J Respir Crit Care Med 2004; 170 (2) 109-113
  CrossrefPubMedGoogle Scholar
• 94 de Groote P, Millaire A, Foucher-Hossein C , et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 1998; 32 (4) 948-954
  CrossrefPubMedGoogle Scholar
• 95 Polak JF, Holman BL, Wynne J, Colucci WS. Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol 1983; 2 (2) 217-224
  CrossrefPubMedGoogle Scholar
• 96 Meluzin J, Spinarová L, Hude P , et al. Combined right ventricular systolic and diastolic dysfunction represents a strong determinant of poor prognosis in patients with symptomatic heart failure. Int J Cardiol 2005; 105 (2) 164-173
  CrossrefPubMedGoogle Scholar
• 97 Bursi F, McNallan SM, Redfield MM , et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 2012; 59 (3) 222-231
  CrossrefPubMedGoogle Scholar
• 98 Szwejkowski BR, Elder DH, Shearer F , et al. Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. Eur J Heart Fail 2012; 14 (2) 162-167
  CrossrefPubMedGoogle Scholar
• 99 La Vecchia L, Zanolla L, Varotto L , et al. Reduced right ventricular ejection fraction as a marker for idiopathic dilated cardiomyopathy compared with ischemic left ventricular dysfunction. Am Heart J 2001; 142 (1) 181-189
  CrossrefPubMedGoogle Scholar
• 100 Cappola TP, Felker GM, Kao WH, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002; 105 (14) 1663-1668
  CrossrefPubMedGoogle Scholar
• 101 Leeman M, Van Cutsem M, Vachiéry JL, Antoine M, Leclerc JL. Determinants of right ventricular failure after heart transplantation. Acta Cardiol 1996; 51 (5) 441-449
  PubMedGoogle Scholar
• 102 Addonizio LJ, Gersony WM, Robbins RC , et al. Elevated pulmonary vascular resistance and cardiac transplantation. Circulation 1987; 76 (5 Pt 2) V52-V55
  CrossrefPubMedGoogle Scholar
• 103 Murali S, Kormos RL, Uretsky BF , et al. Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J 1993; 126 (4) 896-904
  CrossrefPubMedGoogle Scholar
• 104 Kirklin JK, Naftel DC, Kirklin JW, Blackstone EH, White-Williams C, Bourge RC. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 1988; 7 (5) 331-336
  PubMedGoogle Scholar
• 105 Tenderich G, Koerner MM, Stuettgen B , et al. Does preexisting elevated pulmonary vascular resistance (transpulmonary gradient > 15 mm Hg or > 5 wood) predict early and long-term results after orthotopic heart transplantation?. Transplant Proc 1998; 30 (4) 1130-1131
  CrossrefPubMedGoogle Scholar
• 106 Erickson KW, Costanzo-Nordin MR, O'Sullivan EJ , et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant 1990; 9 (5) 526-537
  PubMedGoogle Scholar
• 107 Natale ME, Piña IL. Evaluation of pulmonary hypertension in heart transplant candidates. Curr Opin Cardiol 2003; 18 (2) 136-140
  CrossrefPubMedGoogle Scholar
• 108 Cimato TR, Jessup M. Recipient selection in cardiac transplantation: contraindications and risk factors for mortality. J Heart Lung Transplant 2002; 21 (11) 1161-1173
  CrossrefPubMedGoogle Scholar
• 109 Klotz S, Deng MC, Hanafy D , et al. Reversible pulmonary hypertension in heart transplant candidates—pretransplant evaluation and outcome after orthotopic heart transplantation. Eur J Heart Fail 2003; 5 (5) 645-653
  CrossrefPubMedGoogle Scholar
• 110 Villanueva FS, Murali S, Uretsky BF , et al. Resolution of severe pulmonary hypertension after heterotopic cardiac transplantation. J Am Coll Cardiol 1989; 14 (5) 1239-1243
  CrossrefPubMedGoogle Scholar
• 111 Rabinovitch M. Pulmonary hypertension: pathophysiology as a basis for clinical decision making. J Heart Lung Transplant 1999; 18 (11) 1041-1053
  CrossrefPubMedGoogle Scholar
• 112 Kjaergaard J, Akkan D, Iversen KK , et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007; 99 (8) 1146-1150
  CrossrefPubMedGoogle Scholar
• 113 Hart SA, Krasuski RA, Wang A, Kisslo K, Harrison JK, Bashore TM. Pulmonary hypertension and elevated transpulmonary gradient in patients with mitral stenosis. J Heart Valve Dis 2010; 19 (6) 708-715
  PubMedGoogle Scholar
• 114 Ader R, Chatterjee K, Ports T, Brundage B, Hiramatsu B, Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation 1980; 61 (5) 931-937
  CrossrefPubMedGoogle Scholar
• 115 Regitz-Zagrosek V, Neuss M, Fleck E. Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects. Eur Heart J 1995; 16 (Suppl N): 86-91
  PubMedGoogle Scholar
• 116 Silke B. Haemodynamic impact of diuretic therapy in chronic heart failure. Cardiology 1994; 84 (Suppl. 02) 115-123
  CrossrefPubMedGoogle Scholar
• 117 Micha T. Maeder, MD, David M. Kaye Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2009; 53: 905-918
  CrossrefPubMedGoogle Scholar
• 118 Yip GW, Frenneaux M, Sanderson JE. Heart failure with a normal ejection fraction: new developments. Heart 2009; 95 (19) 1549-1552
  CrossrefPubMedGoogle Scholar
• 119 Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105 (11) 1387-1393
  CrossrefPubMedGoogle Scholar
• 120 Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002; 105 (12) 1503-1508
  CrossrefPubMedGoogle Scholar
• 121 Yusuf S, Pfeffer MA, Swedberg K , et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362 (9386) 777-781
  CrossrefPubMedGoogle Scholar
• 122 Sueta CA, Gheorghiade M, Adams Jr KF , et al; Epoprostenol Multicenter Research Group Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol 1995; 75 (3) 34A-43A
  CrossrefPubMedGoogle Scholar
• 123 Montalescot G, Drobinski G, Meurin P , et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol 1998; 82 (6) 749-755
  CrossrefPubMedGoogle Scholar
• 124 Califf RM, Adams KF, McKenna WJ , et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134 (1) 44-54
  CrossrefPubMedGoogle Scholar
• 125 Patrono C, Pugliese F, Ciabattoni G , et al. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J Clin Invest 1982; 69 (1) 231-239
  CrossrefPubMedGoogle Scholar
• 126 Sablotzki A, Czeslick E, Schubert S , et al. Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension. Can J Anaesth 2002; 49 (10) 1076-1080
  CrossrefPubMedGoogle Scholar
• 127 Radovancevic B, Vrtovec B, Thomas CD , et al. Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates. J Heart Lung Transplant 2005; 24 (6) 690-695
  CrossrefPubMedGoogle Scholar
• 128 Kiowski W, Sütsch G, Hunziker P , et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346 (8977) 732-736
  CrossrefPubMedGoogle Scholar
• 129 Ooi H, Colucci WS, Givertz MM. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation 2002; 106 (13) 1618-1621
  CrossrefPubMedGoogle Scholar
• 130 Zolk O, Quattek J, Seeland U, El-Armouche A, Eschenhagen T, Böhm M. Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2)27 rats. Cardiovasc Res 2002; 53 (2) 363-371
  CrossrefPubMedGoogle Scholar
• 131 Miyauchi T, Fujimori A, Maeda S , et al. Chronic administration of an endothelin-A receptor antagonist improves exercise capacity in rats with myocardial infarction-induced congestive heart failure. J Cardiovasc Pharmacol 2004; 44 (Suppl. 01) S64-S67
  CrossrefPubMedGoogle Scholar
• 132 Torre-Amione G, Young JB, Durand J-B , et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001; 103 (7) 973-980
  CrossrefPubMedGoogle Scholar
• 133 Torre-Amione G, Young JB, Colucci WS , et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003; 42 (1) 140-147
  CrossrefPubMedGoogle Scholar
• 134 Sütsch G, Kiowski W, Yan XW , et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998; 98 (21) 2262-2268
  CrossrefPubMedGoogle Scholar
• 135 Packer M, McMurray J, Massie BM , et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005; 11 (1) 12-20
  CrossrefPubMedGoogle Scholar
• 136 Packer M. Effects of the endothelin antagonist bosentan on the morbidity and mortality in patients with chronic heart failure. Results of the ENABLE 1 and 2 trial program. Presented at the College of Cardiology Meeting, March 2002
  PubMedGoogle Scholar
• 137 Lüscher TF, Enseleit F, Pacher R , et al; Heart Failure ET(A) Receptor Blockade Trial. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002; 106 (21) 2666-2672
  CrossrefPubMedGoogle Scholar
• 138 Anand I, McMurray J, Cohn JN , et al; EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364 (9431) 347-354
  CrossrefPubMedGoogle Scholar
• 139 Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?. J Card Fail 2002; 8 (3) 124-127
  CrossrefPubMedGoogle Scholar
• 140 Perez-Villa F, Farrero M, Cardona M , et al. Bosentan in heart transplantation candidates with severe pulmonary hypertension: efficacy, safety and outcome after transplantation. Clin Transplant 2013; 27 (1) 25-31
  CrossrefPubMedGoogle Scholar
• 141 Katz SD, Hryniewicz K, Hriljac I , et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005; 111 (3) 310-314
  CrossrefPubMedGoogle Scholar
• 142 Katz SD, Schwarz M, Yuen J, LeJemtel TH. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993; 88 (1) 55-61
  CrossrefPubMedGoogle Scholar
• 143 Koelling TM, Kirmse M, Di Salvo TG, Dec GW, Zapol WM, Semigran MJ. Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol 1998; 81 (12) 1494-1497
  CrossrefPubMedGoogle Scholar
• 144 Guazzi M. Sildenafil and phosphodiesterase-5 inhibitors for heart failure. Curr Heart Fail Rep 2008; 5 (2) 110-114
  CrossrefPubMedGoogle Scholar
• 145 Guazzi M, Vicenzi M, Arena R. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Fail 2012; 14 (1) 82-90
  CrossrefPubMedGoogle Scholar
• 146 Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007; 101 (11) 1084-1095
  CrossrefPubMedGoogle Scholar
• 147 Takimoto E, Champion HC, Li M , et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11 (2) 214-222
  CrossrefPubMedGoogle Scholar
• 148 Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005; 280 (13) 12944-12955
  CrossrefPubMedGoogle Scholar
• 149 Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005; 111 (13) 1601-1610
  CrossrefPubMedGoogle Scholar
• 150 Pérez NG, Piaggio MR, Ennis IL , et al. Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension 2007; 49 (5) 1095-1103
  CrossrefPubMedGoogle Scholar
• 151 Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004; 44 (12) 2339-2348
  CrossrefPubMedGoogle Scholar
• 152 Lewis GD, Lachmann J, Camuso J , et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007; 115 (1) 59-66
  CrossrefPubMedGoogle Scholar
• 153 Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50 (22) 2136-2144
  CrossrefPubMedGoogle Scholar
• 154 Lewis GD, Shah R, Shahzad K , et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116 (14) 1555-1562
  CrossrefPubMedGoogle Scholar
• 155 Zakliczynski M, Maruszewski M, Pyka L , et al. Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates. Transplant Proc 2007; 39 (9) 2856-2858
  CrossrefPubMedGoogle Scholar
• 156 Tedford RJ, Hemnes AR, Russell SD , et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008; 1 (4) 213-219
  CrossrefPubMedGoogle Scholar
• 157 Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008; 14 (3) 189-197
  CrossrefPubMedGoogle Scholar
• 158 Packer M, Carver JR, Rodeheffer RJ , et al; The PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325 (21) 1468-1475
  CrossrefPubMedGoogle Scholar
• 159 Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124 (2) 164-174
  CrossrefPubMedGoogle Scholar
• 160 Guazzi M, Arena R, Ascione A, Piepoli M, Guazzi MD ; Gruppo di Studio Fisiologia dell'Esercizio, Cardiologia dello Sport e Riabilitazione Cardiovascolare of the Italian Society of Cardiology. Exercise oscillatory breathing and increased ventilation to carbon dioxide production slope in heart failure: an unfavorable combination with high prognostic value. Am Heart J 2007; 153 (5) 859-867
  CrossrefPubMedGoogle Scholar
• 161 Guazzi M, Raimondo R, Vicenzi M , et al. Exercise oscillatory ventilation may predict sudden cardiac death in heart failure patients. J Am Coll Cardiol 2007; 50 (4) 299-308
  CrossrefPubMedGoogle Scholar
• 162 Sun XG, Hansen JE, Beshai JF, Wasserman K. Oscillatory breathing and exercise gas exchange abnormalities prognosticate early mortality and morbidity in heart failure. J Am Coll Cardiol 2010; 55 (17) 1814-1823
  CrossrefPubMedGoogle Scholar
• 163 Rosenhek R, Rader F, Klaar U , et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 2006; 113 (18) 2238-2244
  CrossrefPubMedGoogle Scholar
• 164 Fattouch K, Sbraga F, Bianco G , et al. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg 2005; 20 (2) 171-176
  CrossrefPubMedGoogle Scholar
• 165 Riedel B. The pathophysiology and management of perioperative pulmonary hypertension with specific emphasis on the period following cardiac surgery. Int Anesthesiol Clin 1999; 37 (2) 55-79
  PubMedGoogle Scholar
• 166 Dávila-Román VG, Waggoner AD, Hopkins WE, Barzilai B. Right ventricular dysfunction in low output syndrome after cardiac operations: assessment by transesophageal echocardiography. Ann Thorac Surg 1995; 60 (4) 1081-1086
  CrossrefPubMedGoogle Scholar
• 167 Rex S, Schaelte G, Metzelder S , et al. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. Acta Anaesthesiol Scand 2008; 52 (1) 65-72
  PubMedGoogle Scholar
• 168 Malouf JF, Enriquez-Sarano M, Pellikka PA , et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol 2002; 40 (4) 789-795
  CrossrefPubMedGoogle Scholar
• 169 Khot UN, Novaro GM, Popović ZB , et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003; 348 (18) 1756-1763
  CrossrefPubMedGoogle Scholar